Over the past 4 decades, outcomes have improved dramatically among pediatric patients with acute lymphoblastic leukemia (ALL), with observed cure rates now .80% in developed countries. 1 This progress can be attributed, in part, to large cooperative group studies, advances in combination chemotherapy, monitoring of minimal residual disease, and use of tyrosine kinase inhibitors (TKIs) for Philadelphia chromosome-positive (Ph 1 ) ALL. Recent series have reported excellent outcomes among adolescents and younger adults with ALL who have been treated with pediatric-inspired regimens. [2] [3] [4] Despite these advances, 5-year overall survival (OS) remains dismal (;20%) among adults age $60 years treated at academic centers and on multiinstitutional clinical trials by using established first-line regimens. 5, 6 European population-based analyses have similarly revealed suboptimal outcomes in this population. [7] [8] [9] [10] Emerging novel agents provide substantial antileukemic effect with manageable toxicity and may represent attractive therapeutic strategies for older patients with ALL, either as components of initial therapy or as treatment at relapse. [11] [12] [13] [14] [15] There remains a paucity of data reflecting clinical outcomes in older US adults with ALL, particularly outside clinical trials, which provides historical context for evaluating novel approaches. Therefore, we used the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) database to describe secular trends of median OS and long-term clinical outcome over the past 4 decades in US adults age $60 years with ALL.
We identified 12 891 patients with ALL from SEER-9 registries by using the International Classification of Diseases for Oncology, third revision (ICD-O-3) codes (http://seer.cancer.gov/siterecode/icdo3_ dwhoheme/index.html). Of 1707 patients age $60 years diagnosed in 1980 or later, 1675 had known survival time and were included for analysis of characteristics associated with OS. OS was defined as months from diagnosis until death or study cutoff (December 31, 2012).
Patients surviving ,1 month from diagnosis are recorded in the SEER database as surviving 0 months. Median survival and 95% confidence intervals (95% CIs) were estimated by using Kaplan-Meier methods. Three study time periods were predetermined by year of diagnosis (1980-1989, 1990-1999, 2000-2011) . Demographic characteristics and county attributes were evaluated for association with OS by using Cox regression. Significant factors (P , .05) in univariable analysis were selected for multivariable analysis. Statistical analyses were performed by using SAS 9.4 (SAS Institute, Cary, NC).
Among 1675 adults diagnosed with ALL at age $60 years between 1980 and 2011 with known OS reported to SEER registries, there were 1517 deaths. Median OS was 4 months (95% CI, 3-5 months). Threeyear OS was 12.8% (95% CI, 11.2%-14.5%), with median follow-up of 26 months (range, 0-286 months) among survivors. Age at diagnosis, time period of diagnosis, known history of cancer preceding ALL diagnosis, and SEER registry region were associated with OS (supplemental Table 1 7 Other recent European registry studies have also noted 3-year OS #15% to 20% among adults with ALL age 60 to 65 years or older. [8] [9] [10] This study describes a greater number of patients age $60 years, confirms that OS has improved modestly (albeit significantly) in older adults since 1980, and is strengthened by multivariable analysis as noted above.
Several causes likely contribute to the poor outcomes observed, even among medically fit adults with ALL age $60 years, including a greater proportion of patients with Ph 1 ALL, increased rates of induction failure, and decreased tolerance of cytotoxic therapy and prolonged myelosuppression. In 1 report of 197 patients treated per CALGB 8811, 3-year OS was only 17% among patients age $60 years (n 5 18) vs 69% among patients age 16 to 30 years and 39% among those age 30 to 59 years. 17 Among patients at MD Anderson Cancer Center treated with a hyperfractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone (hyper-CVAD) regimen, 5-year OS was 20% among patients age $60 years (n 5 122) vs 48% in younger patients receiving hyper-CVAD vs 9% among patients age $60 years receiving earlier VAD (vincristine, doxorubicin, and dexamethasone) -based regimens. Patients age $60 years experienced significantly greater rates of induction failure and treatmentrelated mortality, the latter largely attributable to infection. 5 Analysis of 100 adults age 55 to 64 years treated per Medical Research Council UKALL XII/ECOG 2993 similarly reported decreased likelihood of achieving complete response (CR) compared with patients age 14 to 54 years (73% vs 93%), increased incidence of infections during induction chemotherapy (67% vs 45%), and more frequent omissions, delays, or dose reductions of planned therapy; asparaginase was the most commonly omitted agent. Patients age 55 to 64 years (vs 14-54 years) experienced inferior 5-year event-free survival (19% vs 37%) and 5-year OS (21% vs 41%). 6 Challenges observed in adapting pediatric-inspired approaches to older adults include optimizing use of asparaginase, corticosteroids, and vincristine to balance efficacy and tolerability. Several pediatric-inspired adult ALL protocols have excluded older patients entirely. 2, 3, 18 Advances in TKI therapy have improved outcomes among patients with Ph 1 ALL, comprising .40% of older adults with B-cell ALL (B-ALL) in some series. 19 Several reports have demonstrated high rates of morphologic CR after induction with TKI and corticosteroid therapy alone, with minimal toxicity. 20 Incorporation of second-and third-generation TKIs (vs imatinib) into first-line regimens may further improve outcomes, although direct comparisons are lacking. 21, 22 The European Working Group on Adult ALL recently reported 3-year OS of 41% among patients age $55 years with Ph 1 ALL treated with low-intensity chemotherapy, dasatinib, and corticosteroids. 23 Several new therapies for B-ALL, including blinatumomab and inotuzumab, also seem to be acceptably tolerated in older adults and are associated with high rates and durability of CR compared with historically used salvage chemotherapy regimens. [11] [12] [13] [14] Investigational use of CD19-targeted chimeric antigen receptor T cells also holds promise, although experience in older adults remains decidedly limited. 24, 25 Investigators from MD Anderson Cancer Center have combined inotuzumab with low-intensity hyper-CVAD (cyclophosphamide and dexamethasone at 50% dose reduction and no anthracycline, called mini-hyper-CVD) with or without rituximab in 34 adults age $60 years with newly diagnosed B-ALL, noting CR or pathologic CR in 97% and 2-year OS of 70%. 15 Ongoing clinical trials are additionally investigating blinatumomab in combination with first-line therapy in older adults with B-ALL. The registry data herein underscore the limited gains realized from 1980 to 2011 among older adults with ALL in the United States and may serve as a historical standard by which to evaluate these investigational approaches in this patient population. However, peripheral monocytosis is not pathognomonic of CMML and can be observed in other hematologic neoplasms and benign reactive conditions. Further, monocytes are now recognized as 3 functionally and immunophenotypically distinct cell populations. These populations include classical monocytes (immunophenotypically defined as CD14 Upon stimulation with lipopolysaccharide, classical monocytes produce the highest levels and broadest range of cytokines that include granulocyte colony-stimulating factor, interleukin 10 (IL-10), CCL2, and IL-6.
2 Stimulated nonclassical subsets produce comparatively higher levels of tumor necrosis factor-a and IL-1B, and intermediate monocytes produce all of these cytokines at significantly lower levels. 2 In humans, ;90% of monocytes are comprised of a classical subset and 10% are comprised of nonclassical or intermediate monocytes. 3 Recently, Selimoglu-Buet et al annotated the composition of monocyte subsets in patients with CMML. Utilizing flow cytometry to segregate monocyte subsets, the authors demonstrated that classical monocytes were uniformly increased in CMML. 4 They further demonstrated that classical monocytosis (CM) was a highly specific marker capable of accurately distinguishing CMML from reactive conditions in a mixed cohort of hematologic neoplasms even without considering total monocyte count, genetic, or cytogenetic data. 4 Although these data suggests that monocyte partitioning may serve as a compelling diagnostic marker for this disease, the aforementioned study has been the only report to date describing this observation. Further, given the close genetic and clinical association between myelodysplastic
